A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma

Thomas Elmer Witzig, Grzegorz S Nowakowski, Thomas Matthew Habermann, A. Goy, F. J. Hernandez-Ilizaliturri, A. Chiappella, U. Vitolo, N. Fowler, M. S. Czuczman

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in relapsed/refractory aggressive and indolent B-cell NHL, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, and follicular lymphoma. Based on the pivotal phase II MCL-001 trial of lenalidomide in heavily pretreated patients with relapsed/refractory MCL, lenalidomide was approved by the US Food and Drug Administration for the treatment of relapsed/refractory MCL after failure of two prior therapies, one of which includes bortezomib, at a recommended starting dose of 25 mg on days 1-21 of each 28-day cycle. Lenalidomide enhanced the survival benefit in combination with rituximab in preclinical models, prompting clinical evaluation of the lenalidomide- rituximab (R2) combination. In phase II trials, lenalidomide 20 mg on days 1-21 in combination with different standarddose rituximab schedules exhibited promising activity in both first-line and relapsed/refractory disease across multiple B-cell NHL subtypes. The feasibility of combining lenalidomide with immunochemotherapy, including R-CHOP and rituximab- bendamustine, has been demonstrated in phase I/II trials. These latter regimens are currently being evaluated in ongoing phase II and III trials. The role of lenalidomide monotherapy and R2 in maintenance therapy is also being examined. Based on available evidence, a comprehensive review of lenalidomide in all treatment phases of B-cell NHL- relapsed/refractory disease, first-line, and maintenance-is presented here.

Original languageEnglish (US)
Pages (from-to)1667-1677
Number of pages11
JournalAnnals of Oncology
Volume26
Issue number8
DOIs
StatePublished - 2015

Fingerprint

B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Mantle-Cell Lymphoma
Therapeutics
lenalidomide
Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
Immunologic Factors
United States Food and Drug Administration
Appointments and Schedules
Maintenance
Survival
Rituximab

Keywords

  • Diffuse large B-cell lymphoma
  • Follicular lymphoma
  • Lenalidomide
  • Mantle cell lymphoma
  • Non-Hodgkin lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. / Witzig, Thomas Elmer; Nowakowski, Grzegorz S; Habermann, Thomas Matthew; Goy, A.; Hernandez-Ilizaliturri, F. J.; Chiappella, A.; Vitolo, U.; Fowler, N.; Czuczman, M. S.

In: Annals of Oncology, Vol. 26, No. 8, 2015, p. 1667-1677.

Research output: Contribution to journalArticle

Witzig, TE, Nowakowski, GS, Habermann, TM, Goy, A, Hernandez-Ilizaliturri, FJ, Chiappella, A, Vitolo, U, Fowler, N & Czuczman, MS 2015, 'A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma', Annals of Oncology, vol. 26, no. 8, pp. 1667-1677. https://doi.org/10.1093/annonc/mdv102
Witzig, Thomas Elmer ; Nowakowski, Grzegorz S ; Habermann, Thomas Matthew ; Goy, A. ; Hernandez-Ilizaliturri, F. J. ; Chiappella, A. ; Vitolo, U. ; Fowler, N. ; Czuczman, M. S. / A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. In: Annals of Oncology. 2015 ; Vol. 26, No. 8. pp. 1667-1677.
@article{a9fc127c844f475a86644277480aa591,
title = "A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma",
abstract = "Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in relapsed/refractory aggressive and indolent B-cell NHL, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, and follicular lymphoma. Based on the pivotal phase II MCL-001 trial of lenalidomide in heavily pretreated patients with relapsed/refractory MCL, lenalidomide was approved by the US Food and Drug Administration for the treatment of relapsed/refractory MCL after failure of two prior therapies, one of which includes bortezomib, at a recommended starting dose of 25 mg on days 1-21 of each 28-day cycle. Lenalidomide enhanced the survival benefit in combination with rituximab in preclinical models, prompting clinical evaluation of the lenalidomide- rituximab (R2) combination. In phase II trials, lenalidomide 20 mg on days 1-21 in combination with different standarddose rituximab schedules exhibited promising activity in both first-line and relapsed/refractory disease across multiple B-cell NHL subtypes. The feasibility of combining lenalidomide with immunochemotherapy, including R-CHOP and rituximab- bendamustine, has been demonstrated in phase I/II trials. These latter regimens are currently being evaluated in ongoing phase II and III trials. The role of lenalidomide monotherapy and R2 in maintenance therapy is also being examined. Based on available evidence, a comprehensive review of lenalidomide in all treatment phases of B-cell NHL- relapsed/refractory disease, first-line, and maintenance-is presented here.",
keywords = "Diffuse large B-cell lymphoma, Follicular lymphoma, Lenalidomide, Mantle cell lymphoma, Non-Hodgkin lymphoma, Rituximab",
author = "Witzig, {Thomas Elmer} and Nowakowski, {Grzegorz S} and Habermann, {Thomas Matthew} and A. Goy and Hernandez-Ilizaliturri, {F. J.} and A. Chiappella and U. Vitolo and N. Fowler and Czuczman, {M. S.}",
year = "2015",
doi = "10.1093/annonc/mdv102",
language = "English (US)",
volume = "26",
pages = "1667--1677",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma

AU - Witzig, Thomas Elmer

AU - Nowakowski, Grzegorz S

AU - Habermann, Thomas Matthew

AU - Goy, A.

AU - Hernandez-Ilizaliturri, F. J.

AU - Chiappella, A.

AU - Vitolo, U.

AU - Fowler, N.

AU - Czuczman, M. S.

PY - 2015

Y1 - 2015

N2 - Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in relapsed/refractory aggressive and indolent B-cell NHL, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, and follicular lymphoma. Based on the pivotal phase II MCL-001 trial of lenalidomide in heavily pretreated patients with relapsed/refractory MCL, lenalidomide was approved by the US Food and Drug Administration for the treatment of relapsed/refractory MCL after failure of two prior therapies, one of which includes bortezomib, at a recommended starting dose of 25 mg on days 1-21 of each 28-day cycle. Lenalidomide enhanced the survival benefit in combination with rituximab in preclinical models, prompting clinical evaluation of the lenalidomide- rituximab (R2) combination. In phase II trials, lenalidomide 20 mg on days 1-21 in combination with different standarddose rituximab schedules exhibited promising activity in both first-line and relapsed/refractory disease across multiple B-cell NHL subtypes. The feasibility of combining lenalidomide with immunochemotherapy, including R-CHOP and rituximab- bendamustine, has been demonstrated in phase I/II trials. These latter regimens are currently being evaluated in ongoing phase II and III trials. The role of lenalidomide monotherapy and R2 in maintenance therapy is also being examined. Based on available evidence, a comprehensive review of lenalidomide in all treatment phases of B-cell NHL- relapsed/refractory disease, first-line, and maintenance-is presented here.

AB - Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in relapsed/refractory aggressive and indolent B-cell NHL, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, and follicular lymphoma. Based on the pivotal phase II MCL-001 trial of lenalidomide in heavily pretreated patients with relapsed/refractory MCL, lenalidomide was approved by the US Food and Drug Administration for the treatment of relapsed/refractory MCL after failure of two prior therapies, one of which includes bortezomib, at a recommended starting dose of 25 mg on days 1-21 of each 28-day cycle. Lenalidomide enhanced the survival benefit in combination with rituximab in preclinical models, prompting clinical evaluation of the lenalidomide- rituximab (R2) combination. In phase II trials, lenalidomide 20 mg on days 1-21 in combination with different standarddose rituximab schedules exhibited promising activity in both first-line and relapsed/refractory disease across multiple B-cell NHL subtypes. The feasibility of combining lenalidomide with immunochemotherapy, including R-CHOP and rituximab- bendamustine, has been demonstrated in phase I/II trials. These latter regimens are currently being evaluated in ongoing phase II and III trials. The role of lenalidomide monotherapy and R2 in maintenance therapy is also being examined. Based on available evidence, a comprehensive review of lenalidomide in all treatment phases of B-cell NHL- relapsed/refractory disease, first-line, and maintenance-is presented here.

KW - Diffuse large B-cell lymphoma

KW - Follicular lymphoma

KW - Lenalidomide

KW - Mantle cell lymphoma

KW - Non-Hodgkin lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84937708862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937708862&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdv102

DO - 10.1093/annonc/mdv102

M3 - Article

C2 - 25712458

AN - SCOPUS:84937708862

VL - 26

SP - 1667

EP - 1677

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 8

ER -